ABIO vs. ACHV, TKNO, VNRX, ICCC, AWH, OCX, CDIO, TRIB, BMRA, and MYMD
Should you be buying ARCA biopharma stock or one of its competitors? The main competitors of ARCA biopharma include Achieve Life Sciences (ACHV), Alpha Teknova (TKNO), VolitionRx (VNRX), ImmuCell (ICCC), Aspira Women's Health (AWH), OncoCyte (OCX), Cardio Diagnostics (CDIO), Trinity Biotech (TRIB), Biomerica (BMRA), and MyMD Pharmaceuticals (MYMD). These companies are all part of the "diagnostic substances" industry.
Achieve Life Sciences (NASDAQ:ACHV) and ARCA biopharma (NASDAQ:ABIO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, community ranking, valuation, earnings and risk.
In the previous week, Achieve Life Sciences had 2 more articles in the media than ARCA biopharma. MarketBeat recorded 3 mentions for Achieve Life Sciences and 1 mentions for ARCA biopharma. ARCA biopharma's average media sentiment score of 0.69 beat Achieve Life Sciences' score of 0.47 indicating that Achieve Life Sciences is being referred to more favorably in the media.
Achieve Life Sciences has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Comparatively, ARCA biopharma has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500.
ARCA biopharma is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.
33.5% of Achieve Life Sciences shares are held by institutional investors. Comparatively, 56.4% of ARCA biopharma shares are held by institutional investors. 2.0% of Achieve Life Sciences shares are held by insiders. Comparatively, 30.9% of ARCA biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Achieve Life Sciences received 207 more outperform votes than ARCA biopharma when rated by MarketBeat users. Likewise, 70.21% of users gave Achieve Life Sciences an outperform vote while only 41.98% of users gave ARCA biopharma an outperform vote.
Achieve Life Sciences currently has a consensus target price of $14.00, suggesting a potential upside of 168.20%. Given ARCA biopharma's higher possible upside, equities research analysts plainly believe Achieve Life Sciences is more favorable than ARCA biopharma.
Achieve Life Sciences' return on equity of -16.08% beat ARCA biopharma's return on equity.
Summary
Achieve Life Sciences beats ARCA biopharma on 8 of the 14 factors compared between the two stocks.
Get ARCA biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ARCA biopharma Competitors List
Related Companies and Tools
